Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Ponders Next Move After English HTA Rejects Oxbryta Again Despite Appeal

Executive Summary

In spite of successfully appealing against previous negative guidance, Pfizer has again failed to secure a positive recommendation from England’s health technology appraisal institute for Oxbryta for hemolytic anemia caused by sickle cell disease, and has been asked to provide more evidence.

You may also be interested in...



Stock Watch: Risk And The Pharmaceutical Discount Rate

In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.

Blow For Pfizer As UK's NICE Rejects Oxbryta For Sickle Cell Disease

Oxbryta is a highly lauded, first-in-class treatment for sickle cell anemia, a serious and lifelong health condition that can cause pain, infections, organ damage and strokes. But preliminary draft guidance from England’s HTA body says the product is not an acceptable use of National Health Service resources.

Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy

In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel